Mohsen Zena, MD
Endocrinology, Diabetes & Metabolism · Omaha, NENPI 1548436033
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.5% of the total across 246 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 38 manufacturers, the largest accounting for just 17.8% — the pattern of someone who eats at a lot of different presentations.
Across 246 payments — averaging $16.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$719
- Abbott$363
- Novo Nordisk$359
- Sanofi-aventis U.S. LLC$344
- Amgen$232
- Ascensia Diabetes Care US Inc.$195
- plus $2K from 32 others
What the payments were for
- Food & beverage$3,94698%
- Education$1002%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 50 | $719 |
| Abbott | 17 | $363 |
| Novo Nordisk | 28 | $359 |
| Sanofi-aventis U.S. LLC | 20 | $344 |
| Amgen | 15 | $232 |
| Ascensia Diabetes Care US Inc. | 11 | $195 |
| Radius Health, Inc. | 9 | $181 |
| Bayer | 8 | $151 |
| Pfizer | 8 | $134 |
| AstraZeneca(2 entities) | 9 | $126 |
| Recordati_rare_diseases_inc. | 5 | $114 |
| Boehringer Ingelheim | 6 | $102 |
| Xeris Pharmaceuticals, Inc. | 6 | $102 |
| Novartis | 6 | $99 |
| Insulet Corporation | 4 | $88 |
| AbbVie | 4 | $74 |
| Sumitomo Pharma America, Inc. | 4 | $62 |
| Antares Pharma, Inc. | 3 | $56 |
| Kyowa Kirin, Inc. | 3 | $48 |
| Averitas Pharma Inc. | 2 | $47 |
| Otsuka America Pharmaceutical, Inc. | 2 | $42 |
| Dexcom, Inc. | 3 | $41 |
| Zealand Pharma US, Inc. | 3 | $39 |
| Amphastar Pharmaceuticals, Inc. | 2 | $37 |
| Amryt Pharma Holdings Ltd | 2 | $35 |
| Mannkind Corporation | 2 | $30 |
| Merck | 2 | $26 |
| Actelion Pharmaceuticals US, Inc. | 1 | $25 |
| Johnson & Johnson | 2 | $24 |
| Amarin Pharma, Inc. | 1 | $21 |
| Astellas Pharma US Inc | 1 | $20 |
| Ultragenyx Pharmaceutical Inc. | 1 | $19 |
| Neurocrine Biosciences, Inc. | 1 | $19 |
| Exact Sciences | 1 | $16 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
| Chiesi USA, Inc. | 1 | $15 |
| GSK | 1 | $13 |
| Valeritas, Inc. | 1 | $11 |
How this compares
$4,046 in reported general payments places this provider in the 65th percentile of 43 endocrinology, diabetes & metabolism providers in Nebraska.
See all endocrinology, diabetes & metabolism providers in Nebraska →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 358 | $449,920 |
| TrulicityDulaglutide | 308 | $365,543 |
| JardianceEmpagliflozin | 325 | $316,484 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 80 | $124,251 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 74 | $97,444 |
| MounjaroTirzepatide | 85 | $93,922 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 106 | $91,993 |
| Tresiba Flextouch U-200Insulin Degludec | 74 | $74,436 |
| Bydureon BciseExenatide Microspheres | 29 | $51,239 |
| FarxigaDapagliflozin Propanediol | 50 | $46,074 |
| JanuviaSitagliptin Phosphate | 29 | $43,698 |
| Tresiba Flextouch U-100Insulin Degludec | 73 | $43,075 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 260 | $35,225 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 61 | $27,176 |
| Humalog Kwikpen U-100Insulin Lispro | 108 | $23,850 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro, Humalog, Lyumjev, Baqsimi | $719 | $492,704467 claims |
| Novo NordiskOzempic, Novolog | $359 | $453,050373 claims |
| Boehringer IngelheimJardiance | $102 | $316,484325 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus | $344 | $104,224115 claims |
| MerckJanuvia, Janumet | $26 | $51,11343 claims |
| AstraZenecaFarxiga | $126 | $46,07450 claims |
| BayerKerendia | $151 | $11,69814 claims |
| AbbVieSynthroid | $74 | $6,22250 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 43 endocrinology, diabetes & metabolism providers in Nebraska.
Other endocrinology, diabetes & metabolism in Omaha
- Marium IlahiOmaha$170K
- Cyrus DesouzaOmaha$86K
- Timothy WahlOmaha$41K
- Leslie EilandOmaha$17K
- Anupam KotwalOmaha$17K
- John GallagherOmaha$15K
- Andjela DrincicOmaha$14K
- Laura Graeff-ArmasOmaha$11K
- Claire BakerOmaha$6K
- Alain TaylonOmaha$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.